In the treatment of patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), the first-in-class GLP-1/glucagon dual-receptor agonist cotadutide confers positive effects on body weight, alanine aminotransferase levels, and markers of liver fat and fibrosis, although these benefits appear to come with adverse gastrointestinal events, as shown in a phase IIb study.
Safety data from the phase III IMbrave150 trial reinforce the previously reported favourable safety profile of atezolizumab-bevacizumab compared with sorafenib for unresectable hepatocellular carcinoma (HCC).
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
Proton beam radiotherapy (PBT) was noninferior to radiofrequency ablation (RFA) for local progression-free survival (LPFS) in patients with recurrent hepatocellular carcinoma (rHCC), in addition to showing a tolerable safety profile, according to the APROH trial presented during the 2020 digital ILC.
The combination therapy sofosbuvir-seraprevir appears to be effective and well tolerated in patients with chronic hepatitis C virus (HCV) genotype 1 infection without cirrhosis, results of a phase III trial have shown.